anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Chronic pelvic discontinuity is a challenge during revision total hip arthroplasty due to the loss of structural continuity of the superior and inferior aspects of the acetabulum from severe acetabular bone loss. Acetabular distraction provides an alternative surgical treatment by stabilizing the acetabular component through elastic recoil of the pelvis, which may be supplemented with modular porous augments for addressing major acetabular defects. This study reports 2-year radiographic findings following acetabular distraction for the treatment of chronic pelvic discontinuity.
METHODS: Patients undergoing acetabular distraction performed by 5 surgeons from 2002 to 2021 were identified across 5 institutions. Demographic, surgical, and postoperative outcomes, including radiographic component stability, were recorded. There were 53 of 91 (58.2%) patients (5 deceased, 33 lost to follow-up) consisting of 4 Paprosky IIC (7.5%), 8 Paprosky IIIA (15.1%), and 41 Paprosky IIIB (77.4%) defects included, with a mean follow-up time of 4.8 years (range, 2 to 13.5). Modular porous augments were used in 33 (62.3%) cases. Failure was defined as a subsequent revision of the acetabular construct.
RESULTS: Among the 13 (24.5%) patients who returned to the operating room, 6 (46.2%) had a prior history of revision total hip arthroplasty before undergoing acetabular distraction. Only 5 (9.4%) patients underwent acetabular revision following acetabular distraction, leading to an overall cup survivorship of 90.6%. Of the remaining 48 patients, 46 (95.8%) had evidence of radiographic bridging callus of the chronic pelvic discontinuity at their last clinical follow-up.
CONCLUSIONS: To our knowledge, in the largest series to date, acetabular distraction has proven to be a viable treatment for acetabular bone loss with a chronic pelvic discontinuity, with excellent early survivorship and radiographic evidence of bridging callus. Future studies with longer follow-ups are needed to further monitor the efficacy of this technique.
LEVEL OF EVIDENCE: Level III, Retrospective Comparative Study.
PURPOSE: To observe postoperative histological changes in the anterior part of the posterior fixation suture after a Faden operation in an animal model.
METHODS: A posterior fixation suture was placed at two points 6 mm posterior to the insertion of the extraocular muscle on the superior rectus muscle of the right eye in eight rabbits. The superior rectus muscle of the left eye was used as a control. The eyes were enucleated and the anterior portion of the posterior fixation suture, including the myoscleral junction, was extracted 4 weeks after surgery. Postoperative adhesion was graded from 0 to 4 based on histologic findings (hematoxylin-eosin and Masson's trichrome staining).
RESULTS: Histological evaluation revealed diffuse fibrosis at the myoscleral junction and the anterior part of the posterior fixation suture after the Faden operation. The graded scores for fibrosis, acute inflammation, chronic inflammation, and foreign body reactions in the Faden operation group were significantly higher than those in the control group (P < .05). Postoperative diffuse fibrosis of the myoscleral junction and anterior-to-posterior fixation sutures were observed in an animal model.
CONCLUSIONS: Histologic changes may affect ocular alignment and motility, making reoperation unpredictable after the Faden procedure. [J Pediatr Ophthalmol Strabismus. 2024;61(5):371-375.].
This study seeks to conduct translational work that extends rich preclinical findings to the clinical domain to validate whether neuroinflammatory dysregulation is strongly tied to anhedonia. This project addresses critical gaps in the scientific literature by recruiting a chronically stressed sample of individuals-employment seeking individuals who report significant stress-- and will use an experimental therapeutics approach to attenuate neuroinflammation and assess behavioral changes in motivation.

One major obstacle in understanding how neuroinflammation influences motivation involves technological challenges such that conventional approaches are invasive, expensive, and/or lacking specificity. Although static levels of neuroinflammation in humans have been measured via cross sectional studies, capturing behavioral shifts following experimental manipulation has not been done. This gap limits the ability to develop a more precise understanding of how neuroinflammation causes motivational deficits in humans. The proposed project will employ a mechanistic clinical trial of the anti-\[neuro\]inflammatory agent, minocycline, to address these limitations. In animal models, minocycline has attenuated the deleterious effects of neuroinflammation on neurogenesis, long-term potentiation, and neuronal survival. This study will extend research to humans to examine whether links between neuroinflammation and behavioral responses to a reward-related motivation task differ among chronically stressed individuals taking minocycline and the placebo control. The proposed project will provide preliminary evidence for potential neural targets that have relevance for motivational deficits due to neuroinflammation.

Once screening is complete, participants will come to UNC to complete quality-of-life surveys, learn about the full study schedule, and receive the first dose of medication. This visit will last about 90 minutes. Participants will be asked to participate in two medication periods, meaning they will take both minocycline (antibiotic medication) for 5-days, and an inactive substance (placebo sugar pill) for 5-days. This will investigate whether there are changes in their responses to negative and positive information. After taking the first medication for five days, participants will come in to complete computer tasks (Probabilistic Reward Task, Negative Emotion Dot Probe, and Threatening Visual Search Task) and some follow-up surveys (Snaith-Hamilton Pleasure Scale and Motivation and Pleasure Scale). This visit will last about 90 minutes. Participants will then get at least a 2-week break before taking the second medication for five days. Then, they will come back for another 90-minute visit to complete the same computer tasks and follow-up surveys. The total study duration including the break is about one month. The total time in study sessions on campus over the month will be 4.5 hours.
An application generation and implementation method and system. The application generation method includes receiving by a computing device from an application server, a copy of an application framework. The computing device retrieves reusable software engine implementations and reusable software component implementations. The computing device receives from a developer, first application code associated with the reusable software engine implementations and the reusable software component implementations. The computing device receives from the developer, second application code associating the reusable software component implementations and the reusable software engine implementations with data stored in databases. The computing device receives from the developer, third application code associated with locally or remotely accessible application services. The computing device generates and stores a transparency software application comprising the first, second, and third application software code.
Based on anecdotal reports at MRMC, and as a follow up to a 2020 research study, evidence-based practice research council (EBPRC) members and staff asked colleagues about stress-producing events in their scope of work. It was reported that individuals were unclear about available resources and preparation to handle unsafe environments when client/visitor behaviors escalated to aggressive or unsafe situations. The EBPRC members reviewed the MRMC policies related to violence/assault/injury towards MRMC personnel. What remains unclear is if staff are aware of existing policies and are adhering to reporting guidelines pertaining to employee and stakeholder safety. Additionally, based on literature review, the problem of workplace violence perpetrated by patients and visitors is excessive and escalating nationally and internationally. Additionally, at MRMC, the EBPRC acquired documentation of the number of reported assaults, aggressive behavior or violence of stakeholders (patients and visitors) towards healthcare providers that were documented and referred to the MRMC employee health services. From the local hospital's tally, there were 28 cases from January, 10, 2020 to February 4, 2021. Of the 28 cases, seven occurred between February 2, 2021 and February 4, 2021. Hence, it is essential to conduct a study targeting healthcare workers at MRMC to identify opportunities for further intervention that creates a safety-focused, supportive culture.

The Occupational Safety and Health Act and the Occupational Safety and Health Administration require that employees and employers work together to prevent or abate recognized hazardous and cited workplace areas for concerns and develop a successful safety and health management system especially for Healthcare and Social Services workers.
Immune-mediated colitis, which can present as a severe and acute-onset form of colitis, has been reported in patients receiving LEMTRADA in the postmarketing setting. Some cases of colitis were serious, requiring hospitalization. Systemic corticosteroids were required in some of these patients. The time from treatment initiation to onset of symptoms in these cases ranged from a few months to years.

Monitor patients for immune-mediated colitis during and after LEMTRADA treatment, and evaluate promptly if signs and symptoms that may indicate immune-mediated colitis, such as new or persistent diarrhea or other gastrointestinal signs and symptoms, occur.

It is unknown whether immune-mediated colitis in patients treated with LEMTRADA is a monophasic disorder, or whether recurrent flares (as are seen in patients with inflammatory bowel disease) will occur.
Participants will receive roxadustat tablets orally 3 times a week (TIW). The initial dose will be according to the tiered weight-based approach, with starting roxadustat doses of 70 milligrams (mg) TIW to participants weighing \<70 kilograms (kg) and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of ≥11.0 grams/deciliter (g/dL) and Hb increase from baseline (BL) of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 234.9 weeks.
Reduced shear strain and deformability of the thoracolumbar fascia has been linked to low back pain. A number of ultrasound examination methods have been developed for laboratory rather than clinical practice. The aim of this study was to examine the reliability and discriminative validity (patients vs. healthy individuals) of an ultrasound (US) measurement method for the quantification of thoracolumbar fascia deformation (TLFD). A cross-sectional study with US assessment and rater blinding was conducted in a manual therapy clinic and a university laboratory. 16 acute low back pain (aLBP) patients and 15 healthy individuals performed a standardized trunk extension task. US measurements of TLFD were carried out independently by two raters by imaging the TLF in the starting and ending positions of the movement. Intra-rater and inter-rater reliability were calculated using intraclass correlation coefficients (ICCs) and minimal detectable changes (MDC) were calculated. Receiver operating characteristic (ROC) curve analysis was used to determine the cut-off for TLFD to discriminate the study groups. Kappa statistics were performed to assess rater agreement in discrimination. Intra-rater reliability was excellent (ICC: .92, MDC: 5.54 mm, p < .001) and inter-rater reliability was good (ICC: .78, MDC: 8.70 mm, p < .001). The cut-off for TLFD was 6 mm with a sensitivity of 100% and a specificity of 93.75% and the raters agreed moderately (κ = 0.74, p < .001) when distinguishing patients and controls. The reliability of the US method for assessing TLFD is moderate to excellent, and the ability to discriminate aLBP patients from healthy individuals is moderate. The method could be used to capture an additional parameter in morphological aLBP screenings.
The invention discloses a pearl Vitamin E soft capsule made of the Vitamin E, pearl powder, perilla seed oil and soybean oil. After being mixed and grinded, the Vitamin E, the pearl powder, the perilla seed oil and the soybean oil are made into capsule by pelleting on a packaging machine of the soft capsule. The weight parts of components are as follows: 3 to 5 parts of the Vitamin E, 10 to 20 parts of the pearl powder, 3 to 5 parts of the perilla seed oil and 5 to 8 parts of the soybean oil. The Vitamin E and the pearl powder are combined to make the pearl Vitamin E, so the manufacturing process of the invention is easy. And the effective component of the pearl powder is effectively utilized. The Vitamin E and the pearl powder mutually supplement, coordinate nutritional components necessary for people and improve the metabolism function of body, thus achieving dual purpose of body nutritional components supplementation and health care.
The linea alba will be closed to a ratio of 5mm / 5mm. Only the fascia will be sutured ; fat or muscle tissue will be avoided. Subcutaneous tissue will be closed with polyglactin 3/0 suture. The skin will be closed with a stapler.
The invention discloses a zirconium-reinforced immediate-processing microcrystalline glass and a composition thereof, and a preparation method and application thereof, belonging to the technical field of oral medicine. The composition comprises the following components in parts by mole: 40-70 parts of ethyl orthosilicate, 10-20 parts of lithium nitrate, 3-12 parts of potassium nitrate, 1-20 parts of zirconium oxychloride, 0.5-15 parts of aluminum nitrate, 0.5-5 parts of sodium nitrate, 0.5-10 parts of fluorescer, 0.5-10 parts of photosensitizer, 0-10 parts of glass modifier and 0-20 parts of colorant. The preparation method comprises the following steps: sol-gel, melting, pouring/water quenching and die casting, and crystallizing to obtain the product. The method can comprise higher content of colorant than common microcrystalline glass on the premise of not changing the optical and mechanical properties of the microcrystalline glass. The method has the advantages of low production temperature and energy saving. The microcrystalline glass can be used as a dental repair material.
Fifteen participants, between 18 and 35 years of age. Participants are not pregnant; are healthy and suffering from no chronic diseases with the potential to influence vascular function; non-smoker; sedentary (defined via the completion of the international physical activity questionnaire; IPAQ); and were not consuming regularly probiotic-containing products. Additionally, a medical questionnaire was completed to exclude anyone with overt chronic disease.
The following relates generally to the medical monitoring arts, medical warning systems concerning a monitored patient, and so forth. In clinical settings, alarms are usually triggered when a single-parameter or a multi-parameter score exceeds certain thresholds. When a score needs to be determined, if certain parameters are not available, the common practice is to use the most recent measurements of the parameters for the score calculation. However, a patient's status may change from moment to moment. The parameters measured hours ago may not be a good indicator of the patient's current status. This uncertainty can put deteriorating patients at great risk. An embodiment uses statistical methods to estimate a range of scores and the probability of these scores if old measurements have to be used for score determination. Instead of giving a single number at a time, a confidence interval may be displayed to emphasize the fact that the score is determined partially based on old measurements. If there is a chance that the actual score is higher and may exceed a critical alarm threshold, a notification can be issued to advise a new measurement reading to improve score confidence.
INTRODUCTION: Although living kidney donation is generally considered a safe procedure, it is ethically critical that prospective donors are fully informed before consent. However, prospective donors lack a deep understanding of the donation experience, making the postdonation aftermath feel unanticipated. We sought to gain in-depth qualitative descriptions of the short- and long-term risks and benefits associated with kidney donation among an ethnically diverse group of donors to offer a balanced view of the positive and negative experiences that may occur postdonation.
METHODS: We conducted individual narrative in-depth interviews (September 2020-March 2021) using the DIPEx (database of individual patient experiences) method with former living kidney donors primarily via Zoom.
RESULTS: Fourteen donors (10 women; 8 White, 5 Hispanic, and 1 Native American) completed interviews. Interactions with healthcare providers leading up to donation were largely positive; however, lack of clarity regarding postdonation laboratory values among primary care providers led three participants to be erroneously told they developed kidney disease. Most experienced unanticipated outcomes, including postsurgical complications (e.g., hernia), long-term fatigue (i.e., ≥12 weeks), emotional distress (e.g., depression), hypertension, and gout. Difficulty obtaining life insurance following donation was an unexpected challenge. Despite these issues, participants were unanimously enthusiastic about living kidney donation and reported no regrets.
CONCLUSIONS: Enthusiasm for living kidney donation remained high among all participants despite most experiencing negative outcomes. These findings suggest that greater transparency regarding postdonation experiences may not preclude the decision to move forward with living kidney donation. These narratives will be utilized for an online module of lived experiences of donation.
PURPOSE: The SCAF4 gene encodes serine/arginine-related carboxyl-terminal domain-associated factor 4, which is highly expressed in the brain and potentially affects neurodevelopment. However, the functional significance of SCAF4 variants in human diseases remains unknown.
METHODS: Trio-based whole-exome sequencing was performed in three individuals with focal epilepsy. Bioinformatics tools were used to assess the pathogenicity of SCAF4 variants. Knockout scaf4a/b zebrafish were created using CRISPR-Cas9 used to validate the phenotype.
RESULTS: SCAF4 variants were identified in three individuals from three unrelated families with focal epilepsy. All patients had focal seizures and focal discharges on EEG recordings, with intellectual disability or motor retardation, skeletal abnormalities, and one had cryptorchidism. However, no recurrence was observed after short-term ASMs treatment. The identified SCAF4 variants included two nonsense variants and one compound heterozygous variant, consisting of a missense and an in-frame variant. A low frequency of SCAF4 variants was observed in gnomAD in this study. Computational modelling has suggested that missense variants lead to functional impairments. In zebrafish, abnormal epileptiform signals, skeletal development, and neurodevelopment have been found in scaf4a/b knockout compared to wild-type zebrafish.
CONCLUSION: These results indicate that SCAF4 is associated with focal epilepsy accompanied by multisystem disorders. Otherwise, the management of patients with SCAF4 variants requires more attention to multisystem involvement.
Population differences in cardiometabolic disease remain unexplained. Misleading assumptions over genetic explanations are partly due to terminology used to distinguish populations, specifically ancestry, race, and ethnicity. These terms differentially implicate environmental and biological causal pathways, which should inform their use. Genetic variation alone accounts for a limited fraction of population differences in cardiometabolic disease. Research effort should focus on societally driven, lifelong environmental determinants of population differences in disease. Rather than pursuing population stratifiers to personalize medicine, we advocate removing socioeconomic barriers to receipt of and adherence to healthcare interventions, which will have markedly greater impact on improving cardiometabolic outcomes. This requires multidisciplinary collaboration and public and policymaker engagement to address inequalities driven by society rather than biology per se.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to preparing an antibacterial agent as tablets comprising core, intermediate protective layer and envelope. Agent can be used for treatment of infections of upper and lower respiratory ways, septic states, mastitis, osteomyelitis, peritonitis and other suppurative-inflammatory processes. Invention provides preparing antibacterial agent exhibiting stability in storage and easily releasing active substance that provides its high bioavailability. EFFECT: improved properties and enhanced effectiveness of agent. 5 cl, 2 tbl, 2 ex
The goal of replacement therapy is to achieve and maintain a clinical and biochemical euthyroid state. The goal of suppressive therapy is to inhibit growth and/or function of abnormal thyroid tissue. The dose of LEVOTHROID® that is adequate to achieve these goals depends on a variety of factors including the patient's age, body weight, cardiovascular status, concomitant medical conditions, including pregnancy, concomitant medications, and the specific nature of the condition being treated (see WARNINGS and PRECAUTIONS). Hence, the following recommendations serve only as dosing guidelines. Dosing must be individualized and adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters (see PRECAUTIONS, Laboratory Tests).

LEVOTHROID® is administered as a single daily dose, preferably one-half to one hour before breakfast. LEVOTHROID® should be taken at least 4 hours apart from drugs that are known to interfere with its absorption (see PRECAUTIONS, Drug Interactions).

Due to the long half-life of levothyroxine, the peak therapeutic effect at a given dose of levothyroxine sodium may not be attained for 4-6 weeks.

Caution should be exercised when administering LEVOTHROID® to patients with underlying cardiovascular disease, to the elderly, and to those with concomitant adrenal insufficiency (see PRECAUTIONS).